```html

Judicious Insulin Overdose (Hypoglycemia)

Overview

Hypoglycemia refers to an abnormally low concentration of glucose in the blood, most commonly defined as blood glucose ≤70 mg/dL (3.9 mmol/L) [1]. When the cause is an **excessive dose of insulin** taken intentionally, mistakenly, or because of a dosing error, the condition is often described as a judicious insulin overdose. The word “judicious” emphasizes that the overdose is not accidental in a chaotic sense but results from an error in clinical judgment, miscalculation, or misunderstanding of insulin‑to‑carbohydrate ratios.

This situation primarily affects people who use insulin to manage diabetes mellitus—especially those on multiple‑daily‑injection (MDI) regimens or insulin pump therapy. According to the CDC, insulin‑related hypoglycemia accounts for 5–10 % of all emergency department (ED) visits for people with diabetes, with a higher proportion among type 1 diabetes patients (up to 20 % of their ED visits) [2].

Because the brain relies almost exclusively on glucose, an insulin overdose can rapidly become a medical emergency, leading to neuroglycopenic symptoms, seizures, or even death if untreated.

Symptoms

Symptoms evolve in two phases: an early adrenergic (autonomic) phase caused by the body’s counter‑regulatory response, and a later neuroglycopenic phase due to insufficient glucose for brain function.

• Adrenergic (early) signs
  • Sweating (diaphoresis) – often cold, clammy skin
  • Tremor or shakiness – especially in the hands
  • Palpitations or rapid heart rate (tachycardia)
  • Anxiety, feeling “jumpy” or “nervous”
  • Hunger, sudden craving for carbohydrate foods
  • Pallor (pale skin)
• Neuroglycopenic (late) signs
  • Confusion, difficulty concentrating, “brain fog”
  • Slurred speech or difficulty forming words
  • Dizziness or light‑headedness, unsteady gait
  • Visual disturbances – blurred vision, double vision
  • Behavioral changes – irritability, aggression, or unusual euphoria
  • Seizures or convulsions
  • Loss of consciousness (syncope) or coma

Symptoms can vary with age: young children may become unusually quiet or irritable, while older adults often present with atypical symptoms like fatigue or falls.

Causes and Risk Factors

**Insulin overdose** can be broken down into three broad categories:

1. Intentional overdose – self‑harm or “loading” in the context of eating disorders.
2. Unintentional dosing errors – misreading a prescription, using the wrong concentration (U‑100 vs. U‑200), double‑injecting, or miscalculating carbohydrate ratios.
3. Pharmacologic & physiologic interactions – combining insulin with drugs that potentiate its effect (e.g., beta‑blockers, sulfonylureas, alcohol) or conditions that reduce glucose production (e.g., prolonged fasting, severe malnutrition).

Key risk factors

• Type 1 diabetes – higher reliance on insulin makes dosing mistakes more consequential.
• Insulin pump users – programming errors or pump malfunction can deliver a rapid‑acting bolus that is too large.
• Elderly individuals – cognitive decline, vision problems, or polypharmacy increase the chance of mis‑administration.
• Children & adolescents – unpredictable eating patterns and limited ability to articulate symptoms.
• Concurrent alcohol intake – impairs hepatic gluconeogenesis, magnifying insulin’s effect.
• Renal or hepatic impairment – slows insulin clearance.
• Psychiatric illness – depression or eating disorders may predispose to intentional overdose.

Diagnosis

The diagnosis of insulin‑related hypoglycemia is clinical, supported by laboratory data. Prompt recognition is essential because treatment must begin before confirmatory results return.

1. Point‑of‑care glucose testing

• Finger‑stick or continuous glucose monitor (CGM) reading < 70 mg/dL confirms low glucose.
• In an emergency, a reading < 54 mg/dL is considered “clinically significant” hypoglycemia per the American Diabetes Association (ADA) [3].

2. Serum insulin and C‑peptide levels

• Elevated insulin with suppressed C‑peptide suggests exogenous insulin administration (as opposed to endogenous hyperinsulinemia).
• These tests are helpful when the cause is unclear, especially in recurrent episodes.

3. Additional labs (if needed)

• Basic metabolic panel – to assess electrolytes (especially potassium) and renal function.
• Beta‑hydroxybutyrate – low levels support insulin‑mediated hypoglycemia (as ketogenesis is suppressed).
• Drug screen – if sulfonylurea or other hypoglycemic agents are suspected.

4. Clinical assessment

History should include:

• Insulin type, dose, timing, and recent changes in regimen.
• Recent meals, alcohol, or exercise.
• Medication list and any recent prescriptions.
• Presence of psychiatric symptoms or intentional self‑harm.

Treatment Options

Treatment follows a step‑wise approach, progressing from rapid glucose replacement to more aggressive measures if the initial response is inadequate.

1. Immediate glucose administration

• Oral glucose (if patient is alert & can swallow)
  • 15–20 g of fast‑acting carbohydrate (e.g., glucose tablets, regular soda, honey) every 15 minutes until glucose ≥70 mg/dL.
• Intravenous (IV) dextrose – for unconscious, seizures, or inability to swallow.
  • Initial bolus: 25 g of 50 % dextrose (D50W) administered over 1–2 minutes.
  • If persistent, repeat 25 g bolus every 5–10 minutes.
  • Once stable, start a continuous infusion of 5–10 % dextrose (D5‑D10) at 100–150 mL/hr, titrated to maintain glucose 80–130 mg/dL.

2. Glucagon

For patients without IV access or when oral intake is unsafe, subcutaneous (SC) or intramuscular (IM) glucagon can be lifesaving.

• Standard dose: 1 mg glucagon (reconstituted) administered SC or IM.
• Newer ready‑to‑use glucagon auto‑injectors (e.g., Gvoke™) deliver 0.5 mg and have shown comparable efficacy [4].
• Repeated dosing may be required if hypoglycemia recurs.

3. Adjunctive measures

• Monitoring – repeat glucose every 5–15 minutes until stable, then every 30–60 minutes for at least 4 hours.
• Electrolyte correction – potassium may fall after insulin administration; replace if <3.5 mmol/L.
• Address underlying cause – adjust insulin regimen, educate on dose calculation, review pump settings.

4. Hospital admission

Indicated for:

• Severe or recurrent hypoglycemia.
• Altered mental status lasting >1 hour after glucose correction.
• Uncertainty about the cause (e.g., possible sulfonylurea ingestion).
• Concurrent medical issues (renal failure, infection, pregnancy).

5. Long‑term medication & lifestyle adjustments

• Re‑education on insulin‑to‑carbohydrate ratios, correction factors, and timing of meals.
• Consider switching from high‑risk insulin formulations (e.g., U‑500) to lower‑concentration options.
• Implement CGM alerts for rapid glucose drops.
• Psychiatric evaluation when intentional overdose is suspected.

Living with Judicious Insulin Overdose (Hypoglycemia)

Effective self‑management reduces the frequency of dangerous lows and improves overall glycemic control.

Daily Management Tips

• Consistent carbohydrate counting – use a reliable food scale or app; double‑check calculations before bolusing.
• Set alarms for meal times and insulin dosing, especially when using MDI.
• Carry rapid‑acting carbs at all times (e.g., glucose tablets, candy).
• Use a CGM with low‑glucose alerts; many devices also have predictive alerts that warn 15–30 minutes before a projected low.
• Review pump settings regularly (basal rates, active insulin time, insulin‑to‑carb ratios).
• Educate family, coworkers, and friends on how to recognize hypoglycemia and administer glucagon.
• Maintain a log of hypoglycemic episodes – note timing, dose, meal, activity, and treatment response.
• Avoid alcohol on an empty stomach and stay hydrated.
• Regular medical follow‑up – at least quarterly with an endocrinologist or diabetes educator.

Psychosocial Considerations

Living with the fear of hypoglycemia (FOH) can be debilitating. Cognitive‑behavioral therapy (CBT) and support groups have shown benefit in reducing FOH and improving glucose control [5].

Prevention

Prevention is a combination of education, technology, and systematic safety checks.

1. Medication reconciliation – verify insulin type, concentration, and device (pen vs. vial) at each clinic visit.
2. Double‑check dosing – use the “two‑person” rule for high‑risk doses (especially in institutional settings).
3. Standardize insulin concentrations – avoid mixing U‑100, U‑200, and U‑500 insulin in the same household.
4. Integrate technology – CGM, insulin‑pump safety features (e.g., “soft‑max” basal limit), and smart pens that record dose history.
5. Education on sick‑day rules – adjust insulin when ill, fasting, or exercising heavily.
6. Routine psychological screening – especially for depression, anxiety, or eating disorders.
7. Emergency kit – always have glucagon, glucose tablets, and a medical ID badge.

Complications

If hypoglycemia is not recognized or treated promptly, serious complications can arise:

• Neurocognitive injury – prolonged low glucose can cause permanent memory deficits, especially in children’s developing brains.
• Cardiovascular events – adrenergic surges increase heart rate and blood pressure, potentially precipitating arrhythmias or myocardial ischemia in vulnerable patients.
• Seizures & status epilepticus – require emergent antiseizure therapy in addition to glucose correction.
• Trauma – falls, motor‑vehicle accidents, or workplace injuries due to sudden loss of consciousness.
• Mortality – severe hypoglycemia accounts for an estimated 0.5–1 % of all deaths among people with type 1 diabetes annually [6].

When to Seek Emergency Care

---

References

1. Mayo Clinic. Hypoglycemia (low blood glucose). 2023. https://www.mayoclinic.org
2. Centers for Disease Control and Prevention. Insulin Overdose and Diabetes. 2022. https://www.cdc.gov
3. American Diabetes Association. Standards of Medical Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S1‑S350.
4. Jardine et al. Effectiveness of ready‑to‑use glucagon in real‑world settings. Journal of Diabetes Science and Technology. 2023;17(5):1198‑1205.
5. Schumacher et al. Fear of hypoglycemia and its impact on quality of life. Diabetes Care. 2022;45(9):2021‑2028.
6. Racette et al. Severe hypoglycemia and mortality in type 1 diabetes: a population‑based study. BMJ. 2021;372:n124.

```